For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250707:nRSG0451Qa&default-theme=true
RNS Number : 0451Q Venture Life Group PLC 07 July 2025
7 July 2025
VENTURE LIFE GROUP PLC
("Venture Life", "VLG" or the "Company")
Director/PDMR Shareholding
Venture Life (AIM: VLG), a leader in product innovation, development and
commercialisation within the global consumer healthcare sector, announces that
Paul McGreevy, Non-Executive Chairman, has today purchased an aggregate of
66,776 ordinary shares of 0.3 pence each in the capital of the Company
("Ordnary Shares") at a volume-weighted average price of 59.90 pence per
Ordinary Share.
Following the purchases, Mr McGreevy beneficially holds 963,825 Ordinary
Shares representing approximately 0.75 per cent. of the Company's issued share
capital.
For further information, please contact:
Venture Life Group PLC +44 (0) 1344 578004
Jerry Randall, Chief Executive Officer
Daniel Wells, Chief Financial Officer
Cavendish Capital Markets Limited (Nomad and Broker) +44 (0) 20 7720 0500
Stephen Keys / George Lawson (Corporate Finance)
Michael Johnson (Sales)
About Venture Life (www.venture-life.com (http://www.venture-life.com/) )
Venture Life is an international consumer self-care company focused on
commercialising products for the global self-care market. Headquartered in the
UK, the Group's product portfolio includes Balance Activ in the area of
women's intimate healthcare, Earol® supporting ENT care, Lift and Glucogel
product ranges for energy and glucose management and hypoglycaemia, plus the
Health and Her product range supporting the hormonal lifecycle.
The products, which are typically recommended by pharmacists or healthcare
practitioners, are available primarily through health & beauty stores,
pharmacies, grocery multiples and e-commerce channels and are sold globally.
In the UK, Ireland and the USA these are supplied direct by the company to
retailers, elsewhere they are supplied by the Group's international
distribution partners.
The Company makes the following disclosure in accordance with article 19(3) of
the Market Abuse Regulation:
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Paul McGreevy
2 Reason for the notification
a) Position/status Non-Executive Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Venture Life Group plc
b) LEI 213800S8CZUPLAB2KC70
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.3p each in Venture Life Group plc
Identification code
GB00BFPM8908
b) Nature of the transaction Purchase of Ordinary Shares
c) Price(s) and volume(s)
Price Volume
59.80 pence 33,444
60.00 pence 16,666
60.00 pence 16,666
d) Aggregated information 66,776 Ordinary Shares purchased at a volume-weighted average price of 59.90
pence
- Aggregated volume
- Price
e) Date of the transaction 7 July 2025
f) Place of the transaction London Stock Exchange
d)
Aggregated information
- Aggregated volume
- Price
66,776 Ordinary Shares purchased at a volume-weighted average price of 59.90
pence
e)
Date of the transaction
7 July 2025
f)
Place of the transaction
London Stock Exchange
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHFLFLEDDIDIIE